Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:34:44 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



V:NGEN - Nervgen Pharma Corp. - http://www.nervgen.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NGEN - V2.42.13·2.132.72.00    3.98  1.50Apr 18Apr 1715 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolumeBuyerSellerMarkers
        
        
        
        
        
        
        
        
        
        

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2024-04-17 14:20C:NGEN2.02News ReleaseNervgen Pharma's Dec. 31 cash at $11.7-million
2024-04-03 20:43C:NGEN2.34Prospectus ApprovedNervgen Pharma prospectus offering
2024-03-28 13:21C:NGEN2.18News ReleaseNervgen Pharma closes $23.01-million bought deal
2024-03-22 07:38C:NGEN2.49Resume TradingNervgen Pharma resuming at the open
2024-03-21 16:12C:NGEN2.49News ReleaseNervgen Pharma arranges $20-million offering
2024-03-21 15:51C:NGEN2.55Halt TradingNervgen Pharma halted at 12:43 p.m. PT
2024-02-20 17:47C:NGEN3.32News ReleaseNervgen grants options to buy shares
2024-02-15 13:06C:NGEN3.01News ReleaseNervgen to complete NVG-291 enrolment in Q2 2024
2023-11-09 14:25C:NGEN1.96News ReleaseNervgen Pharma's Sept. 30 cash at $14.8-million
2023-11-09 10:12C:NGEN1.96SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-11-09 10:12C:NGEN1.96SEDAR Interim MD & ASEDAR Interim MD & A
2023-10-23 11:30C:NGEN1.79News ReleaseNervgen receives fast-track designation for NVG-291
2023-10-17 13:01C:NGEN1.75News ReleaseNervgen appoints Ruffolo as director
2023-09-25 09:56C:NGEN2.05News ReleaseNervgen doses first patient in spinal cord injury trial
2023-08-09 15:25C:NGEN1.85News ReleaseNervgen cash and investments at $16.1M at June 30
2023-08-09 08:28C:NGEN1.85SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-08-08 11:44C:NGEN1.85News ReleaseNervgen receives IRB OK for NVG-291 trial
2023-06-27 11:11C:NGEN1.71News ReleaseNervgen receives $3.18M (U.S.) grant for NVG-291 trial
2023-06-02 18:20C:NGEN1.70News ReleaseNervgen Pharma extends option expiry by two years
2023-05-23 17:34C:NGEN1.65News ReleaseNervgen grants options to buy 400,000 shares